NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in…
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in…
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT…
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT…
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 15,…
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 15,…
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction…